New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:13 EDTINFIInfinity sees reporting data from both wholly owned clinical programs in 1H13
In the first half of 2013, Infinity expects to report data from both of its wholly owned clinical programs, phosphoinositide-3-kinase and heat shock protein 90, that will inform potential paths to registration. Each program targets areas of unmet patient need such as advanced hematologic malignancies, inflammatory diseases and non-small cell lung cancer. Infinity also announced its second potent, oral PI3K-delta,gamma inhibitor, IPI-443. Nonclinical studies of IPI-443 are now under way, which are designed to enable the initiation of Phase 1 clinical development. Infinity is developing a portfolio of PI3K inhibitors which includes IPI-145 and IPI-443, potent, oral inhibitors of PI3K-delta and PI3K-gamma, as well as retaspimycin hydrochloride, a potent and selective Hsp90 inhibitor.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:07 EDTINFIInfinity Pharma lowers FY15 revenue view to $100M-$120M from $105M-$190M
Consensus is for FY15 revenue $130.6M. Due to changes in the anticipated timing of the initiation of planned clinical studies as well as slower than expected enrollment in DYNAMO+R, Infinity provided the following updated financial guidance for 2015: revenue: Infinity sees FY15 revenue $100M-$120M, compared to prior expectations of $105M-$125M. Sees FY15 net Loss $125M-$145M, compared to prior expectations of $190M-$210M. Sees FY15 cash and Investments balance $230M-$250M, compared to prior expectations of $145M-$165M. This year-end cash and investments includes the $130M milestone payment from AbbVie associated with the completion of patient enrollment in DYNAMO.
October 5, 2015
14:29 EDTINFIInfinity Pharmaceuticals to host research and development day
Subscribe for More Information
September 30, 2015
09:12 EDTINFIInfinity Pharma reaches $130M milestone payment from AbbVie for duvelisib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use